Breaking News
0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Drugmaker Endo settles opioid claims by Tennessee counties, cities for $35 million

Stock MarketsJul 22, 2021 04:55PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. REUTERS/George Frey

By Brendan Pierson

(Reuters) -Endo International Plc has agreed to pay $35 million to settle a lawsuit by Tennessee local governments and on behalf of a child allegedly born addicted to painkillers accusing the drugmaker of fueling the opioid epidemic, the company announced Thursday.

The settlement came just days before the case was set to go to trial to decide damages, in which plaintiffs were expected to seek $2.4 billion. A judge had previously ruled Endo liable as a penalty for failing to hand over evidence.

"We are pleased that after four-plus years of litigation that we have been able to reach an agreement in principle with Endo, and are grateful to the communities of northeast Tennessee for their support in this landmark prosecution," said Gerard Stranch, a lawyer at Branstetter, Stranch & Jennings, who represented the plaintiffs.

The deal must still be approved by some of the plaintiffs, Endo said.

Endo shares had jumped about 25% on Tuesday after local government officials revealed that the drugmaker had made a settlement offer.

The lawsuit, which was filed in 2017, is being pursued by nine counties, 18 cities and a "Baby Doe" allegedly born with neonatal abstinence syndrome, which is caused by withdrawal after in-utero opioid exposure.

The plaintiffs alleged that Endo downplayed the risks of its painkiller Opana ER, which was pulled from the market in 2017 due to concerns about abuse. OxyContin maker Purdue Pharma and generic opioid maker Mallinckrodt (OTC:MNKKQ) Plc were also named as defendants in the case, but subsequently filed for bankruptcy, leaving Endo as the only active defendant.

Chancellor E.G. Moody of the Circuit Court for Sullivan County, who is overseeing the case, ruled in April that Endo and its lawyers engaged in a "coordinated strategy" to withhold evidence, including about opioid prescribers. He took the unusual step of entering judgment of liability against the company as a sanction, leaving only damages to be decided at trial.

Nearly 500,000 people died from opioid overdoses in the United States from 1999 to 2019, according to the U.S. Centers for Disease Control and Prevention. The CDC last week said provisional data showed that 2020 was a record year for overall drug overdose deaths with 93,331, up 29% from a year earlier.

The Tennessee case is among the more than 3,000 lawsuits, mostly by local governments, accusing drugmakers of falsely promoting opioids as safe and distributors and pharmacies of overlooking red flags that drugs were being diverted to illegal channels. The defendants have denied the claims.

U.S. state attorneys general on Wednesday unveiled a settlement proposal in which leading drug distributors McKesson Corp (NYSE:MCK), Cardinal Health Inc (NYSE:CAH) and AmerisourceBergen (NYSE:ABC) Corp would pay a combined $21 billion, and drugmaker Johnson & Johnson (NYSE:JNJ) would pay $5 billion, to resolve most claims against them.

Endo is not part of that deal, and is currently defending itself along with other drugmakers at trials in New York and California. The company in 2019 settled opioid claims by two Ohio counties for $10 million.

Drugmaker Endo settles opioid claims by Tennessee counties, cities for $35 million
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email